Compare SKYE & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYE | NBY |
|---|---|---|
| Founded | 2012 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.1M | 31.6M |
| IPO Year | 2013 | 2007 |
| Metric | SKYE | NBY |
|---|---|---|
| Price | $0.77 | $1.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 178.4K | ★ 608.2K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 35.42 |
| EPS | N/A | ★ 0.76 |
| Revenue | N/A | ★ $370,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $2.57 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.57 | $0.43 |
| 52 Week High | $5.75 | $19.95 |
| Indicator | SKYE | NBY |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 57.82 |
| Support Level | $0.70 | $1.01 |
| Resistance Level | $0.83 | $2.52 |
| Average True Range (ATR) | 0.06 | 0.26 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 51.56 | 96.45 |
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.